These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30537486)

  • 1. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.
    Papachristodoulou A; Signorell RD; Werner B; Brambilla D; Luciani P; Cavusoglu M; Grandjean J; Silginer M; Rudin M; Martin E; Weller M; Roth P; Leroux JC
    J Control Release; 2019 Feb; 295():130-139. PubMed ID: 30537486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
    Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
    Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
    Rahman MA; Gras Navarro A; Brekke J; Engelsen A; Bindesbøll C; Sarowar S; Bahador M; Bifulco E; Goplen D; Waha A; Lie SA; Gjertsen BT; Selheim F; Enger PØ; Simonsen A; Chekenya M
    Br J Cancer; 2019 Oct; 121(7):545-555. PubMed ID: 31413318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
    Koch D; Hundsberger T; Boor S; Kaina B
    J Neurooncol; 2007 Mar; 82(1):85-9. PubMed ID: 17031555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
    J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
    Robinson CG; Palomo JM; Rahmathulla G; McGraw M; Donze J; Liu L; Vogelbaum MA
    Br J Cancer; 2010 Aug; 103(4):498-504. PubMed ID: 20628383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
    Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS
    Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
    Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
    Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
    J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.